Managing Acute Intermediate Risk Pulmonary Thromboembolism in a Patient Who Developed Heparin-Induced Thrombocytopenia: Review of Current Guidelines and Literature

Authors

Blerina Asllanaj, HCA HealthcareFollow
Elizabeth Jane Benge, HCA HealthcareFollow
Sapna Bhatia, HCA HealthcareFollow
Yi McWhorter, HCA HealthcareFollow

Division

Far West

Hospital

MountainView Hospital

Document Type

Case Report

Publication Date

1-1-2023

Keywords

Humans, Male, Heparin, Pulmonary Embolism, Thrombocytopenia, Acute Disease

Disciplines

Cardiovascular Diseases | Critical Care | Internal Medicine

Abstract

Intermediate-risk pulmonary embolism describes hemodynamically stable patients with evidence of right ventricular strain, whereas high-risk pulmonary embolism comprises hemodynamic decompensation resulting in cardiogenic shock. The clinical manifestations of the two aforementioned conditions are challenging to treat in the setting of heparin-induced thrombocytopenia (HIT). Without immediate therapeutic anticoagulation, patients can subsequently deteriorate and require additional advanced therapies, with the end-goal of restoring pulmonary artery perfusion. We present the case of a male with bilateral intermediate-risk pulmonary emboli who developed type 2 HIT prompting different selection of appropriate management strategies.

Publisher or Conference

Journal of Investigative Medicine High Impact Case Reports

Recommended Citation

Asllanaj B, Benge E, Bhatia S, McWhorter Y. Managing Acute Intermediate Risk Pulmonary Thromboembolism in a Patient Who Developed Heparin-Induced Thrombocytopenia: Review of Current Guidelines and Literature. J Investig Med High Impact Case Rep. 2023;11:23247096231166673. doi:10.1177/23247096231166673